Publications

5674 Results

Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B.

Authors
ER Gaynor;S Dahlberg;RI Fisher
Journal / Conference
ASCO 13:370(#1250)
Year
1994
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8516 (INT-0067)

Standard VAD (SWOG-8624) versus total therapy (TT) with 2 autotransplants (AT) for untreated multiple myeloma (MM).

Authors
J Crowley;S Jagannath;S Salmon;DH Vesole;G Tricot;B Barlogie
Journal / Conference
ASCO 13:410(#1401)
Year
1994
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8624

Phase III randomized trial of infusional AZQ (diaziquone) versus IV BCNU for supratentorial malignant astrocytoma (MA): SWOG 8737.

Authors
KA Jaeckle;C Upchurch;SJ Green;HJ Eyre;H Knudsen;R Morantz;FS Vogel;JM Hamilton
Journal / Conference
ASCO 13:177(#496)
Year
1994
Research Committee(s)
Brain
Study Number(s)
SWOG-8737

Concurrent cisplatin/etoposide (PE) plus chest radiation followed by surgery for stages 3A(N2) and 3B non-small cell lung cancer: Completed analysis of SWOG-8805.

Authors
K Albain;V Rusch;J Crowley;A Turrisi;T Rice;R Livingston
Journal / Conference
ASCO 13:337(#1120)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-8805

The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.

Authors
A Lichter;S Green;K Albain;L Hutchins;S Martino
Journal / Conference
ASCO 13:62(#51)
Year
1994
Research Committee(s)
Breast
Study Number(s)
SWOG-8814, SWOG-8897

Intraperitoneal (IP) mitoxantrone vs. intraperitoneal floxuridine in ovarian cancer patients with minimal residual disease after second-look surgery, a randomized phase II pilot.

Authors
F Muggia;D Alberts;P Liu;K Terada;D Wallace
Journal / Conference
ASCO 13:249(#782)
Year
1994
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8835

Phase II evaluation of merbarone in disseminated malignant melanoma: A Southwest Oncology Group study.

Authors
M Slavik;PY Liu;E Kraut;R Natale;V Sondak
Journal / Conference
ASCO 13:398(#1357)
Year
1994
Research Committee(s)
Melanoma
Study Number(s)
SWOG-8913

Cisplatin (P) & etoposide (E) + concurrent thoracic radiotherapy (TRT) administered once versus twice daily for limited-stage (LS) small cell lung cancer (SCLC): Preliminary results of an intergroup trial.

Authors
DH Johnson;K Kim;AT Turrisi;W Sause;R Komaki;H Wagner;R Blum
Journal / Conference
ASCO 13:333(#1105)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-9252 (INT-0115) (EST-3590) (RTOG 91-05) (NCCTG-91-24-51) (CALGB-9393)

Trisomy II in acute myeloid leukemia: a non-random chromosomal aberration associated with a stem cell phenotype.

Authors
ML Slovak;K Kopecky;RE Magenis;D Head;FR Appelbaum;C Willman
Journal / Conference
American Association for Cancer Research 35:194(#1160)
Year
1994

Analysis of Southwest Oncology Group (SWOG) accrual for sex ratios and associated socioeconomic status (SES) factors.

Authors
L Hutchins;D Rector;C Stotts;S Dahlberg;CA Coltman;K Albain
Journal / Conference
ASCO 13:188(#539)
Year
1994